Saturday - April 19, 2025
Tolebrutinib Phase 3 Studies Published, Supporting Review by FDA for Treating Nonrelapsing Secondary Progressive MS
April 11, 2025
NEW YORK, April 11 -- The National Multiple Sclerosis Society issued the following news on April 10, 2025:

* * *

Tolebrutinib Phase 3 Studies Published, Supporting Review by FDA for Treating Nonrelapsing Secondary Progressive MS

The phase 3 studies of oral BTK-inhibitor tolebrutinib have been published in The New England Journal of Medicine. The results provide evidence for tolebrutinib as an effective treatment for nonrelapsing secondary progressive MS* - . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products